TG Therapeutics is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies: TGTX-1101 (ublituximab), which is in clinical development for patients with relapsed and refractory non-Hodgkin’s lymphoma; and TGR-1202, believed to be important in the proliferation and survival of B‐lymphocytes. For more information, visit the company’s Web site: http://www.tgtherapeutics.com
Let us hear your thoughts below: